Skip to content
10-Q

Quarterly Report

ARS Pharmaceuticals, Inc. SPRY

0000950170-25-107618

← back to feed
Filed
Aug 13, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Aug 11, 2025 98.83M sh
Shares Diluted Q2 2025 · Jun 30, 2025 98.36M sh
Shares Diluted Q2 2025 · Jun 30, 2025 98.21M sh
Shares Diluted Q2 2025 · Jun 30, 2024 96.83M sh
Shares Diluted Q2 2025 · Jun 30, 2024 96.66M sh
Capex Q2 2025 · Jun 30, 2025 $142K
Capex Q2 2025 · Jun 30, 2024 $121K
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$80.33M
Operating Cash Flow Q2 2025 · Jun 30, 2024 −$13.99M
Short Term Investments Q2 2025 · Jun 30, 2025 $188.59M
Short Term Investments Q2 2025 · Dec 31, 2024 $263.21M
Cash And Equivalents Q2 2025 · Jun 30, 2025 $51.54M
Cash And Equivalents Q2 2025 · Dec 31, 2024 $50.82M
Stockholders Equity Q2 2025 · Jun 30, 2025 $192.32M
Stockholders Equity Q2 2025 · Mar 31, 2025 $228.97M
Stockholders Equity Q2 2025 · Dec 31, 2024 $256.8M
Stockholders Equity Q2 2025 · Jun 30, 2024 $215.24M
Stockholders Equity Q2 2025 · Mar 31, 2024 $223.87M
Stockholders Equity Q2 2025 · Dec 31, 2023 $230.76M
Current Liabilities Q2 2025 · Jun 30, 2025 $45.6M
Current Liabilities Q2 2025 · Dec 31, 2024 $23.44M
Total Liabilities Q2 2025 · Jun 30, 2025 $121.15M
Total Liabilities Q2 2025 · Dec 31, 2024 $94.36M
Current Assets Q2 2025 · Jun 30, 2025 $281.44M
Current Assets Q2 2025 · Dec 31, 2024 $334.3M
Total Assets Q2 2025 · Jun 30, 2025 $313.47M
Total Assets Q2 2025 · Dec 31, 2024 $351.15M
Eps Diluted Q2 2025 · Jun 30, 2025 −$0.46
Eps Diluted Q2 2025 · Jun 30, 2025 −$0.80
Eps Diluted Q2 2025 · Jun 30, 2024 −$0.13
Eps Diluted Q2 2025 · Jun 30, 2024 −$0.24
Eps Basic Q2 2025 · Jun 30, 2025 −$0.46
Eps Basic Q2 2025 · Jun 30, 2025 −$0.80
Eps Basic Q2 2025 · Jun 30, 2024 −$0.13
Eps Basic Q2 2025 · Jun 30, 2024 −$0.24
Sga Expense Q2 2025 · Jun 30, 2025 $54.31M
Sga Expense Q2 2025 · Jun 30, 2025 $95.42M
Sga Expense restated Q2 2025 · Jun 30, 2024 $8.94M
Sga Expense restated Q2 2025 · Jun 30, 2024 $16.9M
Rd Expense Q2 2025 · Jun 30, 2025 $4.04M
Rd Expense Q2 2025 · Jun 30, 2025 $6.99M
Rd Expense Q2 2025 · Jun 30, 2024 $6.9M
Rd Expense Q2 2025 · Jun 30, 2024 $12.13M
Net Income Q2 2025 · Jun 30, 2025 −$44.88M
Net Income Q2 2025 · Jun 30, 2025 −$78.82M
Net Income Q2 2025 · Jun 30, 2024 −$12.52M
Net Income Q2 2025 · Jun 30, 2024 −$22.81M
Operating Income Q2 2025 · Jun 30, 2025 −$47.61M
Operating Income Q2 2025 · Jun 30, 2025 −$84.79M
Operating Income Q2 2025 · Jun 30, 2024 −$15.34M
Operating Income Q2 2025 · Jun 30, 2024 −$28.53M
Revenue Q2 2025 · Jun 30, 2025 $15.72M
Revenue Q2 2025 · Jun 30, 2025 $23.69M
Revenue Q2 2025 · Jun 30, 2024 $500K
Revenue Q2 2025 · Jun 30, 2024 $500K